Thousand Oaks, CA, United States of America

Longbin Liu

USPTO Granted Patents = 38 (Patent Applications = 10)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 12 (Patent Applications = 19)

Average Co-Inventor Count = 10.6

ph-index = 11

Forward Citations = 383(Granted Patents)

Location History:

Fresno, CA (US) (2010 - 2011)
Thousand Oaks, CA (US) (2001 - 2024)
Los Angeles, CA (US) (2022 - 2024)

Company Filing History:

Chdi Foundation, Inc.

Years Active: 2001-2025

Loading Chart...

38 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12440491 - KRAS G12C inhibitors and methods of using the same (2025-10-14),

2. 12281116 - HTT modulators for treating Huntington's disease (2025-04-21),

3. 12083121 - Substituted piperazines as KRAS G12C inhibitors (2024-09-10),

4. 12083108 - Compounds for targeting mutant huntingtin protein and uses thereof (2024-09-10),

5. 12036292 - Heterobiaryl compounds and imaging agents for imaging huntingtin protein (2024-07-16),

6. 11992535 - Compounds and probes for imaging huntingtin protein (2024-05-28),

7. 11918662 - Heterocyclic compounds and imaging agents for imaging huntingtin protein (2024-03-05),

8. 11905281 - KRAS G12C inhibitors and methods of using the same (2024-02-20),

9. 11806346 - HTT modulators for treating Huntington's disease (2023-11-07),

10. 11766436 - KRAS G12C inhibitors and methods of using the same (2023-09-26),

11. 11389438 - Compounds for targeting mutant huntingtin protein and uses thereof (2022-07-19),

12. 11285156 - Substituted piperazines as KRAS G12C inhibitors (2022-03-29),

13. 11090304 - KRAS G12C inhibitors and methods of using the same (2021-08-17),

14. 11021493 - 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use (2021-06-01),

15. 10519146 - KRAS G12C inhibitors and methods of using the same (2019-12-31),

Title: Innovations and Contributions of Longbin Liu: A Leader in Therapeutic Patent Developments

Introduction: Longbin Liu, based in Thousand Oaks, California, is a prominent inventor renowned for his significant contributions to the field of therapeutic innovations. He boasts an impressive portfolio of 36 patents, with cutting-edge developments focused on combating severe diseases such as cancers and neurodegenerative disorders.

Latest Patents: Among Longbin Liu's latest innovations are two notable patents. The first is centered around "Substituted piperazines as KRAS G12C inhibitors." This patent introduces innovative compounds that serve as KRAS G12C inhibitors, which are crucial for treating several types of cancers, including pancreatic, colorectal, and lung cancers. The second patent pertains to "Compounds for targeting mutant huntingtin protein and uses thereof," which describes compounds that target both the mutant huntingtin protein and an ubiquitin E3 ligase. These agents hold promise for treating neurodegenerative disorders associated with the aggregation of mutant huntingtin.

Career Highlights: During his career, Longbin Liu has made significant achievements while working with reputable organizations. He has contributed his expertise at Amgen Inc., a leader in biotechnology, and the CHDI Foundation, Inc., which is focused on developing therapies for Huntington's disease. His work in these companies has had a profound impact on the advancement of therapeutic interventions.

Collaborations: Collaboration has been a cornerstone of Longbin Liu's career. He has worked alongside distinguished professionals like Aaron C. Siegmund and Shon Booker, with their combined expertise fostering innovation in their respective fields. These partnerships have enabled him to enhance the applicability of his patents and improve therapeutic outcomes for various disorders.

Conclusion: Longbin Liu's exemplary journey in the realm of patents underscores his dedication to medical advancements. His innovative patents, collaborations with talented peers, and experience in esteemed companies have solidified his position as a leading inventor in developing therapeutics to address critical health challenges. As he continues to explore new opportunities, Liu's work will undoubtedly contribute to the future of medicine and enhance patient care.

This text is generated by artificial intelligence and may not be accurate.